On 14 June 2010, a US court backed sanofi-aventis and Albany Molecular Research in their bid to prevent Dr Reddy’s selling a generic version of the anti-allergenic medication, Allegra-D 24 Hour (fexofenadine HCl/pseudoephedrine HCl).
Sanofi-aventis blocks generic Allegra
Generics/News
|
Posted 25/06/2010
0
Post your comment
Albany Molecular Research and sanofi-aventis are partners on Allegra, with Albany Molecular receiving royalties on sales of Allegra and authorised generic versions.
This is a blow for the Indian generics company, Dr Reddy, who gained FDA approval for its generic version of Allegra in March 2010, and had expected to pull in around US$150 million over the next three years from the copy.
According to sanofi-aventis’ first-quarter results, Allegra sales in the first quarter of 2010 were worth Euros 170 million, down 27% on the same period in 2009.
Albany Molecular Research and sanofi-aventis want to continue to market Allegra in the US. Plans by sanofi-aventis to obtain over-the-counter status for the shorter-acting version, Allegra-D 12 Hour remain on track.
Generic versions of Allegra-D 12 Hour already exist, including an authorised copy, which was part of a settlement from an earlier generic challenge.
Research
Japan’s drug shortage crisis: challenges and policy solutions
Saudi FDA drug approvals and GMP inspections: trend analysis
Related content
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment